NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Neuraxis, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$7.85+0.15 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $95.14M
- P/E (TTM)
- –
- Dividend yield
- –
Neuraxis, INC revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| All other States [Member] | $1.25M | $767.99K | $726.48K | $699.13K | 34.9% | +62.2% |
| Canada | $898.22K | $778.21K | $601.24K | $408.65K | 25.2% | +15.4% |
| OH | $578.77K | $431.33K | $407.63K | $500.26K | 16.2% | +34.2% |
| Morocco | $265.20K | $154.41K | $127.30K | – | 7.4% | +71.8% |
| Israel | $222.39K | $246.22K | $117.96K | – | 6.2% | -9.7% |
| WI | $215.43K | $157.79K | $292.60K | $670.25K | 6.0% | +36.5% |
| FL | $143.95K | $149.99K | $186.84K | $231.48K | 4.0% | -4.0% |
| Macao SAR China | – | – | – | $174.98K | – | – |
From the segment and revenue-disaggregation notes of Neuraxis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.